Comparing Vaxxinity (NASDAQ:VAXX) and Actinium Pharmaceuticals (NYSE:ATNM)

Actinium Pharmaceuticals (NYSE:ATNM) and Vaxxinity (NASDAQ:VAXX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, profitability, earnings, institutional ownership and dividends.

Earnings & Valuation

This table compares Actinium Pharmaceuticals and Vaxxinity”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Actinium Pharmaceuticals	N/A	N/A	-$48.82 million	($1.31)	-0.98
Vaxxinity	N/A	N/A	-$56.93 million	($0.45)	0.00

Actinium Pharmaceuticals is trading at a lower price-to-earnings ratio than Vaxxinity, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Actinium Pharmaceuticals and Vaxxinity, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Actinium Pharmaceuticals	0	0	2	0	3.00
Vaxxinity	0	0	0	0	0.00

Actinium Pharmaceuticals currently has a consensus price target of $4.50, suggesting a potential upside of 250.47%. Given Actinium Pharmaceuticals’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Actinium Pharmaceuticals is more favorable than Vaxxinity.

Profitability

This table compares Actinium Pharmaceuticals and Vaxxinity’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Actinium Pharmaceuticals	N/A	-100.85%	-47.89%
Vaxxinity	N/A	N/A	N/A

Institutional & Insider Ownership

27.5% of Actinium Pharmaceuticals shares are owned by institutional investors. Comparatively, 82.9% of Vaxxinity shares are owned by institutional investors. 6.0% of Actinium Pharmaceuticals shares are owned by company insiders. Comparatively, 64.1% of Vaxxinity shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Volatility and Risk

Actinium Pharmaceuticals has a beta of -0.25, suggesting that its stock price is 125% less volatile than the S&P 500. Comparatively, Vaxxinity has a beta of 15.55, suggesting that its stock price is 1,455% more volatile than the S&P 500.

Summary

Vaxxinity beats Actinium Pharmaceuticals on 7 of the 11 factors compared between the two stocks.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company’s research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.

About Vaxxinity

Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology, cardiovascular diseases, and coronaviruses in the United States. Its product pipeline comprises UB-311, which is in phase 2 clinical trial that targets toxic forms of aggregated amyloid-b in the brain to fight alzheimer's disease; UB-312, which is in phase 1 clinical trial that targets toxic forms of aggregated a-synuclein in the brain to fight parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy; and VXX-301, which is in preclinical trial, an anti-tau product candidate for various neurodegenerative conditions, including alzheimer's disease, traumatic brain injury, and chronic traumatic encephalopathy. It also develops VXX-401, which is phase 1 clinical trial that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; UB-313 that targets calcitonin gene-related peptide to fight migraines; and UB-612, neutralizes the SARS-CoV-2 virus and is in phase 3 clinical trial. The company was incorporated in 2021 and is headquartered in Merritt Island, Florida.